Last reviewed · How we verify
NCT06565026
CS-206 in Patients With Sickle Cell Disease
EARLY_PHASE1 trial testing CS-206 in Sickle Cell Disease in 5 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | CorrectSequence Therapeutics Co., Ltd |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 2 September 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CS-206
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sponsor
CorrectSequence Therapeutics Co., Ltd — full company profile →
Who can join
Adults 12 to 35, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in therapeutic gene-editing technologies.
Liu D, Cao D, Han R. · · 2025 · cited 17× · PMID 40119516 · DOI 10.1016/j.ymthe.2025.03.026 -
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects.
Cetin B, Erendor F, Eksi YE, Sanlioglu AD, et al · · 2025 · cited 15× · PMID 40160040 · DOI 10.1017/erm.2025.10 -
CRISPR-based therapeutic genome editing for inherited blood disorders.
Levesque S, Bauer DE. · · 2025 · cited 7× · PMID 40659814 · DOI 10.1038/s41573-025-01236-y -
Clinical Trial Landscape of Gene-Edited Autologous Hematopoietic Stem Cells for Hemoglobinopathies and Immunodeficiencies.
O'Hanlon Cohrt K, O'Dea S. · · 2026 · PMID 42074029 · DOI 10.3390/ijms27083384 -
Advances in CRISPR Base Editing: From Molecular Evolution to Therapeutic Applications in Genomic Medicine.
Aliciaslan M, Erbasan E, Erendor F, Sanlioglu S. · · 2026 · PMID 42033211 · DOI 10.1111/jcmm.71159 -
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond.
Ji R, Chen Q, Zhang Y. · · 2026 · PMID 41418774 · DOI 10.1016/j.xcrm.2025.102459
Verify or expand the search:
- PubMed search for NCT06565026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CS-206
Trials testing the same drug.
- NCT07000318 — CS-206 in Patients With Sickle Cell Disease · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other CorrectSequence Therapeutics Co., Ltd trials
Trials by the same sponsor.
- NCT07489196 — A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major · Phase 2 · not yet recruiting
- NCT06291961 — A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major · Phase 1 · completed
- NCT06328764 — CS-101 in Patients With β-thalassemia · EARLY_PHASE1 · enrolling by invitation
- NCT06024876 — A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06565026 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CorrectSequence Therapeutics Co., Ltd
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06565026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing